| Literature DB >> 31349905 |
Zachary Wilmer Reichenbach1, Mary Grace Murray2, Reshu Saxena2, Daniel Farkas3, Erika G Karassik2, Alena Klochkova2, Kishan Patel2, Caitlin Tice3, Timothy M Hall2, Julie Gang2, Henry P Parkman4, Sarah J Ward5, Marie-Pier Tétreault6, Kelly A Whelan7.
Abstract
Esophageal squamous cell carcinoma (ESCC) is among the most deadly forms of human malignancy characterized by late stage diagnosis, metastasis, therapy resistance and frequent recurrence. Clinical management of ESCC remains challenging and the disease presently lacks approved targeted therapeutics. However, emerging data from recent clinical and translational investigations hold great promise for future progress toward improving patient outcomes in this deadly disease. Here, we review current clinical perspectives in ESCC epidemiology, pathophysiology, and clinical care, highlighting recent advances with potential to impact ESCC prevention, diagnosis and management. We further provide an overview of recent translational investigations contributing to our understanding of the molecular mechanisms underlying ESCC development, progression and therapy response, including insights gained from genetic studies and various murine model systems. Finally, we discuss future perspectives in the clinical and translational realms, along with remaining hurdles that must be overcome to eradicate ESCC.Entities:
Keywords: Clinical; Esophageal squamous cell carcinoma; Esophagus; Mouse models; Pathogenesis; Therapy; Translational
Mesh:
Substances:
Year: 2019 PMID: 31349905 DOI: 10.1016/bs.acr.2019.05.004
Source DB: PubMed Journal: Adv Cancer Res ISSN: 0065-230X Impact factor: 6.242